Abstract
Rheumatoid arthritis (RA) is a common inflammatory disease associated with many extraarticular
features. The aim: of the current study is to assess the influence of omega-3 fatty acids
(EPA, DHA) on serum alkaline phosphatase in patients with active RA. A single blinded placebo
controlled clinical trial with 12 weeks follow up period at which 50 patients with active RA
using methotrexate were randomized into 2 groups to receive either omega-3 (1000 mg) capsule
three times daily or capsules prefilled with glucose as placebo and were evaluated at zero time
(baseline) and after 12 weeks for alkaline phosphatase level in serum. In addition to twenty five
healthy subjects as control group. The age of RA patients in omega-3 group ranged from 25-80
years (50.36±2.46), whereas the age of RA patients in placebo group ranged from 35-68 years
(50.08±1.84 ), while the age of apparently healthy subjects in control group where ranged from
40-60 years (94.20±1.12). The RA disease activity was measured using disease activity score of
28 joints(DAS28-ESR) and clinical disease activity index (CDAI). After 12 weeks of starting
adjuvant treatment with either omega-3 or placebo, the results showed that there were no
significant difference between the effect of omega- 3 and placebo on alkaline phosphatase level.
In Conclusion, omega-3 significantly decreased alkaline phosphatase level in patient with active
rheumatoid arthritis.
features. The aim: of the current study is to assess the influence of omega-3 fatty acids
(EPA, DHA) on serum alkaline phosphatase in patients with active RA. A single blinded placebo
controlled clinical trial with 12 weeks follow up period at which 50 patients with active RA
using methotrexate were randomized into 2 groups to receive either omega-3 (1000 mg) capsule
three times daily or capsules prefilled with glucose as placebo and were evaluated at zero time
(baseline) and after 12 weeks for alkaline phosphatase level in serum. In addition to twenty five
healthy subjects as control group. The age of RA patients in omega-3 group ranged from 25-80
years (50.36±2.46), whereas the age of RA patients in placebo group ranged from 35-68 years
(50.08±1.84 ), while the age of apparently healthy subjects in control group where ranged from
40-60 years (94.20±1.12). The RA disease activity was measured using disease activity score of
28 joints(DAS28-ESR) and clinical disease activity index (CDAI). After 12 weeks of starting
adjuvant treatment with either omega-3 or placebo, the results showed that there were no
significant difference between the effect of omega- 3 and placebo on alkaline phosphatase level.
In Conclusion, omega-3 significantly decreased alkaline phosphatase level in patient with active
rheumatoid arthritis.
Keywords
Active rheumatoid arthritis
alkaline phosphatase.
Methotrexate
Omega-3